contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


new-study-shows-normal-gastropanelr-result-safely-rules-out-need-for-gastroscopy

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Biohit operates in the medical technology sector. The company develops and manufactures laboratory equipment, consumables and diagnostic analysis systems adapted for research, healthcare and industrial laboratories. In addition to its main business, it offers technical support, maintenance and training services within the aforementioned field of work. The largest operations are conducted in the Nordic market. The company has its headquarters in Helsinki.

Of course, the patient’s symptoms, history, and risk factors influence the decision.

My understanding has been that Gastropanel would be a preliminary test, so if it shows green, the patient can be sent home and doesn’t need an endoscopy. If it shows red, then further examinations are ordered. But if there’s still a 10% probability with a green result that further examination is needed, then how can that test result be trusted? I don’t know if I’m misunderstanding the test process or the research result.

Indeed, other factors influence the necessity of gastroscopy besides just the gastropanel result. It is only a very effective tool.

So, what is the reason then that an endoscopy is performed even if Gastropanel shows that the matter is in order? It doesn’t state that. But it also doesn’t say that the Gastropanel result would be wrong in that case. It only states that the examination is done regardless of the result. But then to the point. If nine out of ten endoscopies can be omitted, where an adult has a specialist doctor and a nurse involved in the procedure, or for a child (I don’t know if Gastropanel is suitable for children or if there’s even a need) where an anesthesiologist and a nurse, an examining doctor and an assisting nurse are involved, then certainly money and healthcare personnel’s time are saved.

I’ll open up some more content so that the information isn’t just behind links.   New study: GastroPanel® safely rules out the need for gastroscopy   A recently published clinical study confirms that when the GastroPanel® test result is normal, upper abdominal endoscopy, i.e., gastroscopy, is generally not needed.   This is a significant breakthrough for healthcare systems struggling with tight budgets, rising costs, long queues, and limited specialist resources.  It’s hard to find anything negative about this, quite the opposite. When these articles are published in industry journals, one would think that interest in the company and its product would start to awaken more broadly.  Having experienced the procedure myself, it’s rare to pay hundreds for the pleasure of a beautiful woman holding your hand while a man dressed (at least) as a doctor shoves a tube over a meter long inside you. I would have preferred to do things with GastroPanel.

Isn’t that test result quite bad? If Gastropanel shows that everything is okay, but there’s still a 10% chance that everything isn’t okay. So if additional tests still have to be done, what added value does Gastropanel bring?

This is good for the patient just by avoiding an endoscopy, as it’s not a pleasant procedure.                   Nordnet              Nordnet    Tee säästämisestä osakkeisiin & rahastoihin hauskempaa. Sijoittaminen osakkeisiin, rahastoihin ja ETF:iin ilman tarpeettomia kuluja. Tervetuloa Suomen tyytyväisimpien sijoittajien joukkoon! Avaa tili jo tänään!

Biohit

Biohit Oyj Press Release 8 December 2025 at 10:30 a.m. EESTNew Study Shows Normal GastroPanel® Result Safely Rules Out Need for Gastroscopy Major Cost Savings PossibleA newly published clinical...

Biohit Oyj Press Release 8 December 2025 at 10:30 a.m. EESTNew Study Shows Normal GastroPanel® Result Safely Rules Out Need for Gastroscopy Major Cost Savings PossibleA newly published clinical study confirms that when GastroPanel® results are normal, upper endoscopy (gastroscopy) is typically unnecessary.This is a significant breakthrough for global healthcare systems struggling with tight budgets, rising costs, long waiting lists, and limited specialist capacity.Why this matters<ul><li>Up to 90% of gastroscopies could be avoided when GastroPanel® is normal.</li><li>Gastroscopy is invasive, expensive and resource-intense.</li><li>Eliminating unnecessary procedures could save millions annually while freeing capacity for patients who truly need endoscopy.</li></ul>The research, known as the Kappa-Study, was conducted at Oulu University Hospital and published in <a href="https://ar.iiarjournals.org/content/anticanres/45/12/5491.full.pdf">Anticancer Research (2025).</a> It shows a very high agreement between GastroPanel® results and biopsy histology, confirming the test as a reliable non-invasive triage tool for patients with upper-abdominal symptoms.Biohit CEO Jussi Hahtela: “The results speak clearly: if GastroPanel® is normal, gastroscopy is almost never needed. This is a turning point that could save huge costs and significantly shorten waiting lists.”GastroPanel® is currently gaining international attention as a scalable solution to improve efficiency in gastric diagnostics.For further information, please contact: Jussi Hahtela, CEO, Biohit Oyj tel. +358 9 773 861 <a href="mailto:investor.relations@biohit.fi">investor.relations@biohit.fi </a> <a href="http://www.biohit.fi/">www.biohit.fi</a>Biohit in briefBiohit Oyj is a Finnish biotechnology company that operates internationally. Biohit’s mission is Innovating for Health – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki and has subsidiaries in Italy and the United Kingdom. Biohit’s series B share (BIOBV) is listed on Nasdaq OMX Helsinki in the Small Cap/Healthcare group. <a href="http://www.biohithealthcare.com">www.biohithealthcare.com</a>